1. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
2. The COVID-19 Treatment Guidelines Panel. Statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. Available at:https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/. Accessed February 2, 2022.
3. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Available at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed February 2, 2022.
4. Centers for Disease Control and Prevention (CDC). Influenza antiviral drug resistance. Available at: https://www.cdc.gov/flu/treatment/antiviralresistance.htm. Accessed February 2, 2022.
5. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase;Wainberg;Antimicrob Agents Chemother,2005